Navigation Links
Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Date:7/21/2008

LA JOLLA, Calif., July 21 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) announced today that they have initiated research at their facility in La Jolla, California. Zenobia was founded June 1, 2008, is privately funded and moved into their new laboratory and office facilities on July 1. The Zenobia team are leaders in the areas of high-throughput structural biology and fragment-based lead discovery (FBLD).

Zenobia will focus on limited population diseases that are traditionally not pursued by larger companies. Zenobia combines the early-stage drug discovery method of FBLD with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. "There is a niche for companies that are passionate about applying innovative approaches to diseases that are not being addressed by mainstream drug discovery organizations," says Dr. Vicki Nienaber, President and founder of Zenobia. "Our mission is to find cures for these patients by working with foundations, granting agencies and leading biologists and clinicians." Zenobia will also provide access to their technology through a limited number of collaborations and partnerships.

Vicki Nienaber is well known for her pioneering work in techniques to find potential drug molecules using fragment-based screening and structure-based drug design. Vicki has managed both drug discovery and pre-clinical development programs. She was recently the Chief Scientific Officer at ActiveSight, a division of Rigaku Americas Corporation, where she built a diverse team of protein biochemistry, X-ray crystallography and drug discovery experts. Before that, Dr. Nienaber was the Senior Director of Lead Discovery and Crystallography at SGX Pharmaceuticals, where she oversaw strategic drug discovery and structural biology alliances with Novartis and Eli Lilly and initiated their internal kinase lead discovery project. While at Abbott Laboratories, she was the lead inventor of crystallographic fragment-based screening, co-inventor of the ACTOR robotic system for automated crystal sample handling and a leader in structure-based drug design methods.

Zenobia's 505 Coast Blvd facility is fully equipped for cloning, expression, purification and crystallization of proteins. Contracts are in place with synchrotron facilities for high-throughput data collection and Zenobia's compound library is available for screening. Drug discovery chemistry and pharmacology will be accessed through contract research organizations and consultants.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit http://www.zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
2. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
3. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
10. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... ... Bacterial biofilms, surface adherent communities of bacteria that are encased in a ... and catheter infections to gum disease and the rejection of medical implants. Though ... year, there is currently a paucity of means for preventing their formation or treating ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop and ... downtown Boston at 745 Atlantic Ave. , “We are seeing that even the ... value they provide, not just to patients, but also payers. Having a presence in ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility scientists’ ... American Association of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today ... AAB’s commitment to excellence in clinical laboratory services and regulations. , “We ...
(Date:5/19/2017)... Philadelphia, PA (PRWEB) , ... May 19, 2017 ... ... for its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, ... Pennsylvania, New Jersey and Delaware, are encouraged to submit proposals. QED, now in ...
Breaking Biology Technology:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):